Madopar Cr

Levodopa and benserazide, the active ingredients in Madopar CR, are a dopamine precursor and dopa decarboxylase inhibitor combination presented as a controlled‑release oral tablet for oral use. It treats the motor symptoms of Parkinson's disease in adult patients.

GNH USA supplies Madopar CR as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to global markets. With a robust cold‑chain logistics network, GNH USA ensures product integrity during transit.

Madopar CR is used in the management of Parkinsonian disorders by replenishing central dopamine levels.

Parkinson's disease: improves motor function, reducing bradykinesia, rigidity and tremor. Parkinsonian syndrome: alleviates symptoms in patients with idiopathic disease. Levodopa‑responsive Parkinsonism: restores dopaminergic activity in patients who respond to levodopa therapy.

Madopar CR may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Dizziness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia - Hallucinations or psychosis - Severe hypotension - Cardiac arrhythmias - Neuroleptic malignant syndrome - Severe allergic reactions such as anaphylaxis

When prescribing Madopar CR, clinicians should consider several safety measures.

Dose titration: start with the lowest effective dose and increase gradually to minimize adverse effects. Renal impairment: adjust dosing and monitor renal function in patients with reduced clearance. Cardiovascular disease: monitor blood pressure and heart rate due to risk of orthostatic hypotension. Psychiatric history: observe for hallucinations or confusion, especially in elderly patients. Surgical procedures: withhold the drug before anesthesia to avoid interactions with anesthetic agents. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Madopar CR interacts with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - High‑dose pyridoxine (vitamin B6): reduces levodopa efficacy. - Antipsychotics (dopamine antagonists): antagonize therapeutic effect. - Sympathomimetics (e.g., epinephrine): may cause severe hypertension. - Iron or calcium supplements: impair levodopa absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure lowering effect. - Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome. - Other antiparkinson drugs (COMT inhibitors, MAO‑B inhibitors): may require dose adjustment. - Anticholinergics: may increase anticholinergic burden. - Diuretics: monitor electrolytes and blood pressure.